Aberrant methylation of Reprimo correlates with genetic instability and predicts poor prognosis in pancreatic ductal adenocarcinoma.
about
Prognostic Value of SPARC in Patients with Pancreatic Cancer: A Systematic Review and Meta-Analysis5-Azacytidine enhances the radiosensitivity of CNE2 and SUNE1 cells in vitro and in vivo possibly by altering DNA methylationSMAD4 gene mutations are associated with poor prognosis in pancreatic cancer.The p53 circuit boardPancreatic cancer.Reprimo tissue-specific expression pattern is conserved between zebrafish and human.Epigenetics and pancreatic cancer: pathophysiology and novel treatment aspectsMolecular signatures of pancreatic cancer.Epigenetic mechanisms in commonly occurring cancers.Reprimo as a modulator of cell migration and invasion in the MDA-MB-231 breast cancer cell line.Epigenetics and epigenetic alterations in pancreatic cancer.Roles of SPARC in urothelial carcinogenesis, progression and metastasis.Reprimo, a Potential p53-Dependent Tumor Suppressor Gene, Is Frequently Hypermethylated in Estrogen Receptor α-Positive Breast Cancer.A modified bisulfite conversion method for the detection of DNA methylation.tp53-dependent G2 arrest mediator candidate gene, Reprimo, is down-regulated by promoter hypermethylation in pediatric acute myeloid leukemia.Identification of candidate tumour suppressor genes frequently methylated in renal cell carcinoma.APC promoter is frequently methylated in pancreatic juice of patients with pancreatic carcinomas or periampullary tumors.Expression of RPRM/rprm in the Olfactory System of Embryonic Zebrafish (Danio rerio).Loss of Reprimo and S100A2 expression in human gastric adenocarcinoma.
P2860
Q26770931-DEB4E964-C87E-4247-B751-3AF4E5A2824EQ27312329-0DA38FC2-A237-4AF5-8DF2-3482766E6D3BQ27851475-14C6577D-2B88-492B-AADB-5E19CE6CE83AQ28259725-1B70ED23-E10D-434D-B340-4B66F0583C44Q30490247-672B328A-20A0-464A-9A8C-2F00BF608169Q33745928-0B53AFA1-B085-4A9F-BAB8-CD3518EDDAC0Q33801377-1D3EDC8E-6A2F-4ED0-919B-6DE7633673A7Q33918801-80AC5B66-F188-4402-8B68-9796C3E68C96Q36286662-8F8A3181-33E3-4AF9-8181-A279B3ECD755Q36489832-C2A997F5-3B34-47D4-85E9-5DF5786181FBQ37041763-C00EA77A-D0F3-4122-AF49-8E6F9B85609CQ37687199-73405758-9BD4-4525-9279-F0DC93A4D102Q38623918-A3E88907-FDAE-401C-A887-366ABB16DFD5Q38678543-D1454F28-DEE4-4F94-9FBE-6735EC496323Q38915689-A3D4B922-4553-49C3-BCDA-543170B3F205Q39739609-9E467467-D3AC-4D52-9E64-E45562A06074Q40591832-95D4B0B5-69D4-4EE9-B322-33CEED7F5C32Q52595242-0440B58D-DD51-4E11-A054-F4CB432576B5Q53295389-BAD91FAF-55C1-426D-BD6B-A99809518A9D
P2860
Aberrant methylation of Reprimo correlates with genetic instability and predicts poor prognosis in pancreatic ductal adenocarcinoma.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Aberrant methylation of Reprim ...... creatic ductal adenocarcinoma.
@ast
Aberrant methylation of Reprim ...... creatic ductal adenocarcinoma.
@en
Aberrant methylation of Reprim ...... creatic ductal adenocarcinoma.
@nl
type
label
Aberrant methylation of Reprim ...... creatic ductal adenocarcinoma.
@ast
Aberrant methylation of Reprim ...... creatic ductal adenocarcinoma.
@en
Aberrant methylation of Reprim ...... creatic ductal adenocarcinoma.
@nl
prefLabel
Aberrant methylation of Reprim ...... creatic ductal adenocarcinoma.
@ast
Aberrant methylation of Reprim ...... creatic ductal adenocarcinoma.
@en
Aberrant methylation of Reprim ...... creatic ductal adenocarcinoma.
@nl
P2093
P356
P1433
P1476
Aberrant methylation of Reprim ...... creatic ductal adenocarcinoma.
@en
P2093
Charles J Yeo
Hiroyuki Matsubayashi
Norihiro Sato
Noriyoshi Fukushima
P2860
P304
P356
10.1002/CNCR.21977
P407
P577
2006-07-01T00:00:00Z